Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Metabolic Pathway Analysis and Effectiveness of Tamoxifen in Danish Breast Cancer Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prognostic Significance of HPV DNA and p16INK4a in Anal Cancer: A Systematic Review and Meta-Analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Risk of Anal Cancer Following Benign Anal Disease and Anal Cancer Precursor Lesions: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A Cohort Study of Breast Cancer Risk after 20 Years of Follow-Up of Women Treated with Fertility Drugs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. DBCG Kvalitetsdatabase for Brystkræft – resumé af årsrapport 2020

    Publikation: Bidrag til tidsskriftTidsskriftartikelFormidling

  2. A careful reassessment of anthracycline use in curable breast cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Socioeconomic position and prognosis in premenopausal breast cancer: a population-based cohort study in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Thomas P Ahern
  • Lindsay J Collin
  • James W Baurley
  • Anders Kjærsgaard
  • Rebecca Nash
  • Maret L Maliniak
  • Per Damkier
  • Michael E Zwick
  • R Benjamin Isett
  • Peer M Christiansen
  • Bent Ejlertsen
  • Kristina L Lauridsen
  • Kristina B Christensen
  • Rebecca A Silliman
  • Henrik Toft Sørensen
  • Trine Tramm
  • Stephen Hamilton-Dutoit
  • Timothy L Lash
  • Deirdre Cronin-Fenton
Vis graf over relationer

BACKGROUND: Tamoxifen and its metabolites compete with estrogen to occupy the estrogen receptor. The conventional dose of adjuvant tamoxifen overwhelms estrogen in this competition, reducing breast cancer recurrence risk by nearly half. Phase I metabolism generates active tamoxifen metabolites, and phase II metabolism deactivates them. No earlier pharmacogenetic study has comprehensively evaluated the metabolism and transport pathways, and no earlier study has included a large population of premenopausal women.

METHODS: We completed a cohort study of 5,959 Danish nonmetastatic premenopausal breast cancer patients, in whom 938 recurrences occurred, and a case-control study of 541 recurrent cases in a cohort of Danish predominantly postmenopausal breast cancer patients, all followed for 10 years. We collected formalin-fixed paraffin-embedded tumor blocks and genotyped 32 variants in 15 genes involved in tamoxifen metabolism or transport. We estimated conventional associations for each variant and used prior information about the tamoxifen metabolic path to evaluate the importance of metabolic and transporter pathways.

RESULTS: No individual variant was notably associated with risk of recurrence in either study population. Both studies showed weak evidence of the importance of phase I metabolism in the clinical response to adjuvant tamoxifen therapy.

CONCLUSIONS: Consistent with prior knowledge, our results support the role of phase I metabolic capacity in clinical response to tamoxifen. Nonetheless, no individual variant substantially explained the modest phase I effect on tamoxifen response.

IMPACT: These results are consistent with guidelines recommending against genotype-guided prescribing of tamoxifen, and for the first time provide evidence supporting these guidelines in premenopausal women.

TidsskriftCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Udgave nummer3
Sider (fra-til)582-590
Antal sider9
StatusUdgivet - mar. 2020

Bibliografisk note

©2020 American Association for Cancer Research.

ID: 61370658